CSIMarket


Iovance Biotherapeutics Inc   (IOVA)
Other Ticker:  
 


 

Iovance Biotherapeutics Inc

IOVA's Financial Statements and Analysis



Iovance Biotherapeutics Inc narrowed forth quarter of 2023 net loss per share of $-0.34 compare to net loss per share of $-0.63 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.46 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.34 $  0 Mill
$+0.29     Unch.    



Iovance Biotherapeutics Inc 's Revenue rose by 0 % in forth quarter of 2023 (Dec 31 2023) year on year, to $0 million and advanced by 2.77 % sequentially.


Iovance Biotherapeutics Inc is

More on IOVA's Income Statement



Iovance Biotherapeutics Inc 's in theforth quarter of 2023 recorded net loss of $-116.379 million, an increase from net loss of $-105.319 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on IOVA's Growth

Iovance Biotherapeutics Inc Inventories
In Dec 31 2023 company's net cash and cash equivalents decreased by $-153 million, capital expenditures fell by -3.02216.78%, to $-4 millions compare to same quarter a year ago

More on IOVA's Cash flow Statement


Iovance Biotherapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Iovance Biotherapeutics Inc payed $ -1.54 cash per share, on a free-cash flow basis .

Book value fell by -9.25 % sequentially to $2.49 per share, -14.34% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.51 per share from $ 1.83.

Company repurchased 10.88 million shares or 4.42 % in Dec 31 2023.


More on IOVA's Dividends

 Market Capitalization (Millions) 3,268
 Shares Outstanding (Millions) 235
 Total Debt (Millions $) 1
 Revenue (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -444
 Cash Flow (TTM) (Millions $) -57
 Capital Exp. (TTM) (Millions $) -22
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Iovance Biotherapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Iovance Biotherapeutics Inc had negative $ -1.54 cash flow per share, on a free-cash flow basis .

Book value fell by -9.25 % sequentially to $2.49 per share, -14.34% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.51 per share from $ 1.83.

Company repurchased 10.88 million shares or 4.42 % in Dec 31 2023.


More on IOVA's Balance Sheets

 Market Capitalization (Millions) 3,268
 Shares Outstanding (Millions) 235
 Total Debt (Millions $) 1
 Revenue (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -444
 Cash Flow (TTM) (Millions $) -57
 Capital Exp. (TTM) (Millions $) -22
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Iovance Biotherapeutics Inc Earnings

Financial Challenges Amidst Innovation: Iovance Biotherapeutics Reports Revenue of $0.482 Million for Q4 2023

Iovance Biotherapeutics Inc, a leading biotechnology company, recently announced its financial results for the fourth quarter of 2023. The company reported revenue of $0.482 million for the quarter, with a net shortfall of $-116.379 million. This shortfall was larger than the $-105.319 million reported in the same quarter a year ago, indicating a significant increase in expenses for the company. Additionally, Iovance Biotherapeutics reported a net deficit of $-444.04 million for the fiscal year 2023, with total revenue reaching $1.19 million.
Despite these financial challenges, Iovance Biotherapeutics has made significant progress in advancing its novel polyclonal tumor infiltrating lymphocyte (TIL) ther...

Iovance Biotherapeutics Inc Generates Promising Revenue of $0.469 Million, Fueling Excitement in the Biotech Community

As I sit here poring over the financial results of Iovance Biotherapeutics Inc, I can't help but feel a mix of excitement and curiosity. The biotechnology and pharmaceuticals company has just proclaimed a revenue of $0.469 million in the July to September 30, 2023, fiscal span. While this figure may seem relatively modest, I am particularly interested in the potential behind their innovative polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients.
However, it is important to note that despite this revenue, Iovance Biotherapeutics Inc faced a net deficit of $-113.760 million during the same fiscal span. This figure is bigger than the net deficit of $-99.618 million reported a year ago...

Iovance Biotherapeutics Inc Generates Positive Income of $0.238 Million in Q2 2023 Financial Report, Demonstrating Investor Confidence and Promising Prospects

Iovance Biotherapeutics Inc, a Biotechnology and Pharmaceuticals company, has witnessed a significant increase in its stock value over the past few months. In the last three months alone, the company's stock has gone up by 27.3%, and it has recorded a year-to-date growth of 17.51% in 2023. This positive trend indicates that investors have been showing confidence in the company's prospects and its ability to generate returns.
One of the factors contributing to this upward movement is the company's financial performance. In its fiscal time-frame closing on June 30, 2023, Iovance Biotherapeutics Inc reported revenue of $0.238 million. Although this figure may not appear significant, it represents a positive...

Iovance Biotherapeutics Inc Faces Investor Concerns as Operating Loss Swells to $-110.856 Million in Q1 2023

Investors in Iovance Biotherapeutics Inc may be concerned following the revelation that the company recorded a cumulative net loss of $-412 million during the 12 months ending in the first quarter of 2023. This has resulted in a negative return on equity (ROE) of -81%, a worrying trend for stakeholders.
The company's poor performance in comparison to its peers is also a cause for concern. Within the Biotechnology and Pharmaceuticals industry, 92 other companies had a higher return on equity. Furthermore, the company's total ranking has deteriorated compared to the fourth quarter of 2022 from 0 to 2217, indicating a significant drop...


Date modified: 2024-02-29T16:21:25+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com